Cargando…

Drug conjugates—an emerging approach to treat breast cancer

Breast cancer treatment using a single drug is associated with a high failure rate due, in part, to the heterogeneity of drug response within individuals, nonspecific target action, drug toxicity, and/or development of resistance. Use of dual‐drug therapies, including drug conjugates, may help overc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasan, Mahmud, Leak, Rehana K., Stratford, Robert E., Zlotos, Darius P., Witt‐Enderby, Paula A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032357/ https://www.ncbi.nlm.nih.gov/pubmed/29983986 http://dx.doi.org/10.1002/prp2.417

Ejemplares similares

Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands
por: Zlotos, Darius P., et al.
Publicado: (2022)

Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells
por: Malka, Matthews M., et al.
Publicado: (2021)

Novel Melatonin, Estrogen, and Progesterone Hormone Therapy Demonstrates Anti-Cancer Actions in MCF-7 and MDA-MB-231 Breast Cancer Cells
por: Hasan, Mahmud, et al.
Publicado: (2020)

Crystal structure of 5,11-dihydropyrido[2,3-b][1,4]benzodiazepin-6-one
por: Riad, Noura M., et al.
Publicado: (2015)

Co-administering Melatonin With an Estradiol-Progesterone Menopausal Hormone Therapy Represses Mammary Cancer Development in a Mouse Model of HER2-Positive Breast Cancer
por: Dodda, Balasunder R., et al.
Publicado: (2019)

New spectrofluorimetric methods for determination of melatonin in the presence of N-{2-[1-({3-[2-(acetylamino)ethyl]-5-methoxy-1H-indol-2-yl}methyl)-5-methoxy-1H-indol-3-yl]- ethyl}acetamide: a contaminant in commercial melatonin preparations
por: Darwish, Hany W., et al.
Publicado: (2012)

Erratum to: New spectrofluorimetric methods for determination of melatonin in the presence of N-{2-[1-({3-[2-(acetylamino)ethyl]-5-methoxy-1H-indol-2-yl}methyl)-5-methoxy-1H-indol-3-yl]-ethyl}acetamide: a contaminant in commercial melatonin preparations
por: Darwish, Hany W., et al.
Publicado: (2016)

Activated matriptase as a target to treat breast cancer with a drug conjugate
por: Rather, Gulam M., et al.
Publicado: (2018)

Mechanistic Research for the Student or Educator (Part I of II)
por: Leak, Rehana K., et al.
Publicado: (2022)

Mechanistic Research for the Student or Educator (Part II of II)
por: Leak, Rehana K., et al.
Publicado: (2022)

Melatonin-micronutrients Osteopenia Treatment Study (MOTS): a translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osteopenic women following a one-year double-blind RCT and on osteoblast-osteoclast co-cultures
por: Maria, Sifat, et al.
Publicado: (2017)

Treating Prostate Cancer by Antibody–Drug Conjugates
por: Rosellini, Matteo, et al.
Publicado: (2021)

Neurotransmitter receptors on microglia
por: Liu, Huan, et al.
Publicado: (2016)

Microglia-mediated neuroinflammation and neuroplasticity after stroke
por: Wang, Yuan, et al.
Publicado: (2022)

Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions
por: Yang, Tinglin, et al.
Publicado: (2023)

Antibody–Drug Conjugate to Treat Meningiomas
por: Chen, Kai, et al.
Publicado: (2021)

Functional diversities of myeloid cells in the central nervous system
por: Zhang, Wenting, et al.
Publicado: (2020)

Antibody-drug conjugates—an emerging class of cancer treatment
por: Diamantis, Nikolaos, et al.
Publicado: (2016)

Antibody-Drug Conjugates Used in Breast Cancers
por: Abbas, Aram J., et al.
Publicado: (2021)

Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021)

Semisynthetic Analogues of Toxiferine I and Their Pharmacological Properties at α7 nAChRs, Muscle-Type nAChRs, and the Allosteric Binding Site of Muscarinic M(2) Receptors
por: Zlotos, Darius P., et al.
Publicado: (2014)

Pharmacist and Student Knowledge and Perceptions of Herbal Supplements and Natural Products
por: Stayduhar, Jacey M., et al.
Publicado: (2023)

Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology
por: Esnault, Clara, et al.
Publicado: (2022)

Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
por: Deneka, Alexander Y., et al.
Publicado: (2019)

Discovery of Novel CCR5 Ligands as Anticolorectal Cancer Agents by Sequential Virtual Screening
por: El-Zohairy, Mariam A., et al.
Publicado: (2021)

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
por: Najjar, Mariana K., et al.
Publicado: (2022)

Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders
por: Zhao, Shangfeng, et al.
Publicado: (2014)

Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based Conjugation Approaches
por: Hussain, Ahmad Fawzi, et al.
Publicado: (2021)

Potential of antibody–drug conjugates (ADCs) for cancer therapy
por: Marei, Hany E., et al.
Publicado: (2022)

Computational selection of antibody-drug conjugate targets for breast cancer
por: Fauteux, François, et al.
Publicado: (2015)

Novel antibody–drug conjugates for triple negative breast cancer
por: Nagayama, Aiko, et al.
Publicado: (2020)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
por: Grinda, Thomas, et al.
Publicado: (2023)

Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
por: Chen, Yu‐Fei, et al.
Publicado: (2022)

Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers
por: Si, Yingnan, et al.
Publicado: (2021)

Treatment of endocrine resistant metastatic breast cancer in the era of antibody drug conjugates
por: Heater, Natalie K., et al.
Publicado: (2023)

Melatonin Patterns and Levels During the Human Menstrual Cycle and After Menopause
por: Greendale, Gail A, et al.
Publicado: (2020)

Potential of antibody–drug conjugates and novel therapeutics in breast cancer management
por: Lianos, Georgios D, et al.
Publicado: (2014)

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
por: Grinda, Thomas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dqfp8c9vka2iucji21g42fcg0h